Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo Sells 7,689 Shares of Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 7,689 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $30.03, for a total value of $230,900.67. Following the transaction, the senior vice president now owns 27,265 shares of the company’s stock, valued at approximately $818,767.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Santiago Arroyo also recently made the following trade(s):

  • On Tuesday, January 21st, Santiago Arroyo sold 1,235 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $30.08, for a total value of $37,148.80.

NASDAQ:MNTA opened at $31.88 on Friday. Momenta Pharmaceuticals, Inc. has a 12-month low of $9.51 and a 12-month high of $32.37. The firm has a market capitalization of $3.16 billion, a P/E ratio of -14.69 and a beta of 2.01. The business has a 50 day simple moving average of $26.17 and a 200 day simple moving average of $17.38.

A number of hedge funds have recently made changes to their positions in the business. Municipal Employees Retirement System of Michigan boosted its position in Momenta Pharmaceuticals by 1.7% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 30,210 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 500 shares during the period. Metropolitan Life Insurance Co NY boosted its position in Momenta Pharmaceuticals by 1.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 32,021 shares of the biotechnology company’s stock worth $415,000 after acquiring an additional 596 shares during the period. Amalgamated Bank boosted its position in Momenta Pharmaceuticals by 3.4% during the 4th quarter. Amalgamated Bank now owns 18,956 shares of the biotechnology company’s stock worth $374,000 after acquiring an additional 625 shares during the period. Meeder Asset Management Inc. boosted its position in Momenta Pharmaceuticals by 362.0% during the 4th quarter. Meeder Asset Management Inc. now owns 2,421 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,897 shares during the period. Finally, California State Teachers Retirement System boosted its position in Momenta Pharmaceuticals by 1.4% during the 3rd quarter. California State Teachers Retirement System now owns 153,807 shares of the biotechnology company’s stock worth $1,993,000 after acquiring an additional 2,106 shares during the period. Institutional investors own 97.03% of the company’s stock.

A number of research firms recently issued reports on MNTA. Piper Sandler boosted their price objective on Momenta Pharmaceuticals from to in a research report on Wednesday, February 5th. Stifel Nicolaus restated a “buy” rating and set a $43.00 price objective (up previously from $29.00) on shares of Momenta Pharmaceuticals in a research report on Monday, January 27th. SunTrust Banks boosted their price objective on Momenta Pharmaceuticals to and gave the company a “buy” rating in a research report on Wednesday, January 15th. Wells Fargo & Co began coverage on Momenta Pharmaceuticals in a research report on Wednesday, November 6th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. upgraded Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $14.00 to $30.00 in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $31.79.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Read More: What is the definition of arbitrage?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.